Key Inclusion criteria:~* Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical
criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines
for mild cognitive impairment)~* Evidence of the AD pathological process, as confirmed by CSF tau/A-beta42or
amyloid PET scan~* Demonstrated abnormal memory function~* MMSE score greater than or equal to 22 (â‰¥ 22)~*
Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0~* Availability of a reliable study partner who
accepts to participate in study procedures throughout the 2 years duration of study~* If receiving symptomatic
AD medications, the dosing regimen must have been stable for 3 months prior to screening and until
randomization~* For enrollment in the China extension, patients must have residence in mainland China, Hong
Kong, or Taiwan and be of Chinese ancestry~* For women of childbearing potential: agreement to remain abstinent
(refrain from heterosexual intercourse) or use contraceptive methods~Key
